Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 87, 2015
Previous Article Next Article

Systematic development of novel cationic self-nanoemulsifying drug delivery systems of candesartan cilexetil with enhanced biopharmaceutical performance

Author affiliations

Abstract

The current studies entail systematic development, optimization and evaluation of cationic self-nanoemulsifying drug delivery systems (C-SNEDDS) for enhancing the oral bioavailability of candesartan cilexetil. Preformulation studies including equilibrium solubility studies and phase titration studies facilitated the selection of Lauroglycol 90 (i.e., lipid), Tween 40 (i.e., emulgent) and Transcutol HP (i.e., cosolvent), while oleylamine was used as a cationic charge inducer. D-optimal mixture design was employed for systematic optimization of C-SNEDDS, evaluating them for globule size, zeta potential, in vitro drug release and dissolution efficiency. Mathematical modeling was carried out and optimized formulation was identified through numerical optimization desirability function. Evaluation of the cellular uptake and permeability in Caco-2 cells revealed 2.2-fold increase in apparent permeability (Papp) and 6.4-fold reduction in the P-gp efflux ratio of the candesartan cilexetil from C-SNEDDS vis-à-vis the free drug solution. Nearly 5 to 6-fold enhancement in oral bioavailability was observed with the optimized C-SNEDDS vis-à-vis the plain SNEDDS and free drug solution using in situ single pass intestinal perfusion and in vivo pharmacokinetic studies, both conducted in Wistar rats. Establishment of various levels of in vitro/in vivo correlations (IVIVC) for the developed C-SNEDDS corroborated excellent goodness of fit between the in vitro drug release data with the in vivo absorption parameters. Evaluation of the cytotoxicity of C-SNEDDS by histopathological examination of rat intestine and MTT assay revealed high safety and efficacy of the developed formulations. Overall, the present studies report the successful development of novel C-SNEDDS of candesartan cilexetil with distinctly improved biopharmaceutical performance.

Graphical abstract: Systematic development of novel cationic self-nanoemulsifying drug delivery systems of candesartan cilexetil with enhanced biopharmaceutical performance

Back to tab navigation

Supplementary files

Article information


Submitted
18 Jun 2015
Accepted
14 Aug 2015
First published
14 Aug 2015

RSC Adv., 2015,5, 71500-71513
Article type
Paper
Author version available

Systematic development of novel cationic self-nanoemulsifying drug delivery systems of candesartan cilexetil with enhanced biopharmaceutical performance

G. Sharma, S. Beg, K. Thanki, O. P. Katare, S. Jain, K. Kohli and B. Singh, RSC Adv., 2015, 5, 71500
DOI: 10.1039/C5RA11687B

Social activity

Search articles by author

Spotlight

Advertisements